Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Newswire

Comprehensive Real-Time News Feed for Teva Pharmaceutical Industries.

Results 1 - 20 of 661 in Teva Pharmaceutical Industries

  1. Fitch Affirms Teva's Ratings at 'BBB+'; Outlook StableRead the original story

    1 hr ago | Information Technology

    Fitch Ratings has affirmed the ratings of Teva Pharmaceutical Industries Limited and its subsidiaries at 'BBB+'. The Rating Outlook is Stable.

    Comment?

  2. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    3 hrs ago | Business Wire

    ... rating of its subsidiary Farm Bureau Life In... )--Fitch Ratings has affirmed the ratings of Teva Pharmaceutical Industries Limited (Teva) and its subsidiaries at 'BBB+'. The Rating Outlook is Stable. A full list of rating... )--Fitch Ratings ...

    Comment?

  3. Alexza Amends Autoliv Agreement for Heat Packages Used in ADASUVEARead the original story

    Tuesday | Freshnews

    ... and in several Latin American countries. Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., is Alexza's commercial partner for ADASUVE in the U.S. Grupo Ferrer Internacional, S.A. (Ferrer) is Alexza's commercial ...

    Comment?

  4. "Eosinophilic Esophagitis - Pipeline Review, H2 2014" is now available at Fast Market ResearchRead the original story

    Tuesday | PR-inside.com

    ... that drove them from pipeline Companies Mentioned in this Report: Actavis plc, Novartis AG, Teva Pharmaceutical Industries Limited, DBV Technologies SA, Meritage Pharma, Inc., Oxagen Limited, Dr. Falk Pharma GmbH, Receptos, Inc., Lipella ...

    Comment?

  5. OncoGenex Pharmaceuticals Inc. Announces Completion Of Patient...Read the original story

    Monday | BioSpace

    ... of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, ...

    Comment?

  6. Opko gains $295 million up front for global license to develop, market long-acting HGH.Read the original story w/Photo

    Tuesday | TheStreet.com

    Miami-based Opko gained the compound, hGH-CTP, and its technology to extend the action of biologics with its $480 million all-stock acquisition of Israel's Prolor Biotech Inc. in April 2013. Pfizer was reportedly interested in buying Prolor at the time, which may explain the high price and unusual deal terms.

    Comment?

  7. OncoGenex Announces Completion of Patient Enrollment in the Rainier...Read the original story

    Tuesday | Canada NewsWire

    ... of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, ...

    Comment?

  8. The top biopharmaceutical deals of 2014Read the original story w/Photo

    Monday Dec 15 | Business Journal

    In January, Teva made an unsolicited offer to buy NuPathe Inc. of Malvern, Pa., for $114 million - topping a $105 million offer Endo International put in play at the end of 2013. Teva ultimately bought NuPathe, the developer of the migraine headache treatment Zecuity, for $144 billion in February.

    Comment?

  9. Xenon Pharmaceuticals Inc. Reports Third Quarter 2014 Financial ResultsRead the original story

    Sunday Dec 14 | BioSpace

    ... clinical data in our partnered programs." In the first quarter of 2014, Xenon's partner Teva Pharmaceutical Industries Ltd. initiated a Phase 2b clinical trial for TV-45070 in osteoarthritis with data expected in the third quarter of 2015. Teva ...

    Comment?

  10. Drug Firms Prevail In Antitrust TrialRead the original story w/Photo

    Sunday Dec 14 | Chemical and Engineering News

    ... rgeted two other generic drug makers that struck similar deals with AstraZeneca over Nexium - Teva Pharmaceutical Industries and Dr. Reddy's Laboratories - but both settled with the plaintiffs.

    Comment?

  11. New Market Research Report: Global Huntington's Disease Therapeutics Market 2014-2018Read the original story

    Saturday Dec 13 | PR-inside.com

    ... * Pfizer * Prana Biotechnology * Raptor Pharmaceutical * Siena Biotech * SOM Biotech * Teva Pharmaceutical Industries Market Driver * Unmet Medical Needs * For a full, detailed list, view our report Market Challenge * Poor Diagnosis Rates * For a ...

    Comment?

  12. Teva Upgraded On Strength Of Copaxone MS DrugRead the original story w/Photo

    Friday Dec 12 | Investor's Business Daily

    Teva issued 2015 guidance on Thursday morning, with revenue slightly below expectations but EPS on the high side. The 2015 revenue guidance of $19 billion to $19.4 billion is down from the current 2014 consensus estimate of $20.3 billion based on the assumption that September will bring two generic competitors to Copaxone.

    Comment?

  13. Alexza Pharmaceuticals, Inc. Release: Names ADASUVE In Its "Best Ideas Of 2014"Read the original story

    Thursday Dec 11 | BioSpace

    ... on, the European Commission, and in several Latin American countries. , Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., is Alexza's commercial partner for ADASUVE in the U.S. Ferrer is Alexza's

    Comment?

  14. Why Synta Pharmaceuticals' Inducement Awards To Management Helps ShareholdersRead the original story w/Photo

    Thursday Dec 11 | Seeking Alpha

    I previously discussed the benefits of a management shakeup and the impact of the CEO's compensation but did not predict the new management team or the amount of its awards. Synta Pharmaceuticals Corp .

    Comment?

  15. Teva's 2015 Profit May Beat Estimates on Delayed GenericsRead the original story

    Thursday Dec 11 | The Washington Post

    Teva Pharmaceutical Industries Ltd.'s 2015 profit may surpass analyst estimates if generic copies of bestselling multiple sclerosis drug Copaxone are kept off the market until September. Earnings excluding some costs will be $5 to $5.30 per American depositary receipt in a scenario with two generic versions of once-a-day Copaxone in September, Teva said in a statement today.

    Comment?

  16. Teva foresee lower 2015 revenuesRead the original story

    Thursday Dec 11 | Business World

    Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. Teva is the world's biggest maker of generic drugs but its branded MS drug Copaxone is its most lucrative product, accounting for about 20 percent of sales and 50 percent of profit.

    Comment?

  17. Us Stocks-Futures up as oil bounces ahead of economic dataRead the original story

    Thursday Dec 11 | Reuters

    U.S. stock index futures advanced on Thursday, putting the S&P on track to rebound after a three-day drop as oil prices bounced and ahead of a flurry of economic data. * The benchmark S&P index dropped more than 1 percent on Wednesday and has shed 2.4 percent over the past three sessions, it's worst run in two months, as weakness in oil prices has weighed heavily on the energy sector.

    Comment?

  18. Us Stocks-Wall St to open higher on retail sales liftRead the original story

    Thursday Dec 11 | Reuters

    U.S. stocks were poised for a higher open on Thursday after a three-day drop for the S&P 500 as data pointed to a strengthening economy that appeared likely to overcome the impact of a steep drop in oil prices. The benchmark S&P index dropped more than 1 percent on Wednesday and has shed 2.4 percent over the past three sessions, it's worst run in two months, as weakness in oil prices has weighed heavily on the energy sector.

    Comment?

  19. Schumpeter: The scale-up nationRead the original story w/Photo

    Thursday Dec 11 | The Economist

    ... companies. Only one Israeli firm ranks in the world's 500 largest companies by market cap, Teva Pharmaceutical Industries. This dismal performance, some Israelis explain, is the result of theirs being a small country surrounded by hostile powers. ...

    Comment?

  20. UPDATE 1-Teva Pharm sees 2015 revenue lower than forecastRead the original story

    Thursday Dec 11 | Reuters

    Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. Teva is the world's biggest maker of generic drugs but its branded MS drug Copaxone is its most lucrative product, accounting for about 20 percent of sales and 50 percent of profit.

    Comment?